Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

ESAB vs EKSO: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ESAB Wins Head-to-Head Institutional Verdict (5–0 across 6 Pillars · 8–2 Matrix Metrics)

ESAB Overall Winner 6-Pillar Tally: ESAB 5 – 0 EKSO (1 Tie) Matrix Metrics: ESAB 8 – 2 EKSO

As of Nov 20, 2026, ESAB Corporation (ESAB) is the stronger overall head-to-head candidate over Ekso Bionics Holdings, Inc. (EKSO) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ESAB carries a Unified Composite Score of 27.6/100 (SELL) at $74.74 (11.9x Forward P/E, 14.8% operating margin), whereas EKSO carries 58.1/100 (HOLD) at $11.80 (N/M Forward P/E, -119.7% operating margin).

  • Composite vs. Pillar Nuance: While EKSO currently prints a higher short-term Unified Composite Score (58.1/100 HOLD vs. ESAB 27.6/100 SELL), ESAB captures the overall institutional head-to-head verdict (8–2 matrix metrics and 5–0 across the 6 pillars) due to superior fundamental profitability (14.8% vs. -119.7% operating margin) and revenue trajectory (+13.3% vs. -38.3% YoY).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ESAB vs EKSO
ESAB NYSE Head-to-Head Winner
ESAB Corporation
General Industrial Machinery & Equipment, Nec
$74.74
-3.26% 1D
Market Cap $4.9B
TTM Revenue $3.10B
Forward P/E 11.9x
Beta / 30D Vol 1.77β · 63% Vol
Unified Composite Score
27.6 / 100 SELL
Tech 15.0 Fund 37.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 47
RSI-14: 46.5 · SMA20: $78.10 · SMA50: $71.52
EKSO NASDAQ
Ekso Bionics Holdings, Inc. Common Stock
General Industrial Machinery & Equipment, Nec
$11.80
+0.08% 1D
Market Cap $42.0M
TTM Revenue $13M
Forward P/E N/M
Beta / 30D Vol 2.16β · 76% Vol
Unified Composite Score
58.1 / 100 HOLD
Tech 60.0 Fund 54.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (3.2% over 20 days), RSI 60
RSI-14: 60.4 · SMA20: $10.56 · SMA50: $10.65

6-Pillar Scorecard Institutional Category Breakdown (ESAB 5 – 0 EKSO)

Columns: Metric · ESAB · EKSO
1. Valuation Multiples ESAB
Forward P/E 11.9x N/M
Trailing P/E 28.2x N/M
PEG Ratio 0.80x N/M
EV / Revenue 1.6x 3.3x
2. Growth & Scale ESAB
Revenue Growth (YoY) +13.3% -38.3%
Earnings Growth (YoY) -35.6% +0.0%
TTM Revenue (USD) $3.10B $13M
Market Cap $4.9B $42.0M
3. Profitability & Quality ESAB
Gross Margin 37.6% 53.5%
Operating Margin 14.8% -119.7%
Net Profit Margin 5.1% -91.4%
Return on Equity (ROE) 7.6% -107.6%
4. Balance Sheet & Cash Flow ESAB
Cash Generation (TTM) $578M EBITDA -$11M EBITDA
Cash Flow Margin 18.6% EBITDA Mgn -86.0% EBITDA Mgn
Net Cash / Leverage $38.42 Book/Sh · 7.6% ROE $2.54 Book/Sh · -107.6% ROE
Dividend Yield 0.57% None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile 47.4% (18th %ile) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Markup
6. R&D & Supply-Chain Moat ESAB
OpEx & R&D Intensity 22.8% of Rev ($707M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Metal Fabrication Operator Medical Instruments & Supplies Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ESAB (8) vs EKSO (2)
Institutional Metric ESAB EKSO Criterion Row Edge
Market Capitalization
Scale
$4.9B $42.0M Larger Scale ESAB
Trailing P/E Ratio
Valuation
28.2x N/M Lower Multiple ESAB
Forward P/E Ratio
Valuation
11.9x N/M Lower Multiple ESAB
Revenue Growth (YoY)
Growth
+13.3% -38.3% Higher Growth ESAB
Operating Margin (TTM)
Profitability
14.8% -119.7% Higher Margin ESAB
Net Profit Margin
Profitability
5.1% -91.4% Higher Margin ESAB
Return on Equity (ROE)
Capital Efficiency
7.6% -107.6% Higher ROE ESAB
52-Week Range Position
Momentum
16% ($63–$137) 87% ($0–$14) Stronger Trend EKSO
Beta / 30D Volatility
Risk Regime
1.77β · 63% Vol 2.16β · 76% Vol Lower Realized Risk ESAB
Unified Institutional Score
Composite Signal
27.6 / 100 (SELL) 58.1 / 100 (HOLD) Higher Composite EKSO
Trailing 12M Revenue (USD)
Operating Scale
$3.10B $13M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
37.6% 53.5% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
0.80x PEG · 1.6x EV/Rev N/M PEG · 3.3x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$578M EBITDA ($38.42 Book/Sh · 7.6% ROE) -$11M EBITDA ($2.54 Book/Sh · -107.6% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon EKSO +29.05 pp
ESAB: -3.52% · EKSO: +25.53%
3M Horizon EKSO +43.13 pp
ESAB: -17.2% · EKSO: +25.93%
6M Horizon EKSO +202.37 pp
ESAB: -9.57% · EKSO: +192.8%
1Y Horizon EKSO +202.37 pp
ESAB: -9.57% · EKSO: +192.8%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ESAB vs EKSO. Trailing 12-month operating profitability (ESAB 14.8% vs EKSO -119.7%) and valuation multiples (ESAB 11.9x vs EKSO N/M Forward P/E) are benchmarked directly in Pillar 4 below.

ESAB ADR TTM Benchmark FX-Normalized USD
TTM Revenue$3.10B
Gross Margin37.6%
Op. Margin14.8%
ROE / Fwd P/E7.6% · 11.9x
EKSO ADR TTM Benchmark FX-Normalized USD
TTM Revenue$13M
Gross Margin53.5%
Op. Margin-119.7%
ROE / Fwd P/E-107.6% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ESAB UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 47.4%
IV Percentile 18th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ESAB Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
EKSO UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact EKSO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ESAB Moat Profile Cyclical / Execution-Driven Positioning
Metal Fabrication Operator
Competes within the Metal Fabrication value chain with $4.9B market capitalization and 14.8% operating margin.
OpEx & R&D Reinvestment 22.8% of Rev ($707M)
90D Engineering Disclosures 0 Published
EKSO Moat Profile Cyclical / Execution-Driven Positioning
Medical Instruments & Supplies Operator
Competes within the Medical Instruments & Supplies value chain with $42.0M market capitalization and -119.7% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ ESAB vs EKSO Key Questions & Quantitative Answers

As of Nov 20, 2026, ESAB Corporation (ESAB) is the stronger overall head-to-head candidate over Ekso Bionics Holdings, Inc. (EKSO) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ESAB carries a Unified Composite Score of 27.6/100 (SELL) at $74.74 (11.9x Forward P/E, 14.8% operating margin), whereas EKSO carries 58.1/100 (HOLD) at $11.80 (N/M Forward P/E, -119.7% operating margin). Composite vs. Pillar Nuance: While EKSO currently prints a higher short-term Unified Composite Score (58.1/100 HOLD vs. ESAB 27.6/100 SELL), ESAB captures the overall institutional head-to-head verdict (8–2 matrix metrics and 5–0 across the 6 pillars) due to superior fundamental profitability (14.8% vs. -119.7% operating margin) and revenue trajectory (+13.3% vs. -38.3% YoY).

ESAB leads the Growth & Scale pillar: ESAB posts +13.3% YoY revenue growth and -35.6% YoY earnings growth on $3.10B TTM revenue (37.6% gross margin, 14.8% operating margin), compared with EKSO at -38.3% YoY revenue growth and +0.0% YoY earnings growth on $13M TTM revenue (53.5% gross margin, -119.7% operating margin). On trailing 12-month operating scale, ESAB generates $3.10B in USD-normalized revenue versus $13M for EKSO. In operating R&D and SG&A reinvestment, ESAB deploys 22.8% of Rev ($707M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for EKSO.

ESAB screens cheaper on headline valuation multiples. ESAB trades at 11.9x Forward P/E, 28.2x Trailing P/E, 0.80x PEG, and 1.6x EV/Revenue (18.6% EBITDA margin), whereas EKSO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 3.3x EV/Revenue (-86.0% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ESAB (7.6% ROE) versus EKSO (-107.6% ROE) capital efficiency.

In options market volatility and institutional positioning, ESAB carries 47.4% implied volatility (18th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.77β · 63% Vol realized risk). By comparison, EKSO carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (2.16β · 76% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.